Weekly Twitter Roundup

Posted by Dan Vorhaus on March 5, 2010

Each week there are a number of stories and developments that, for one reason or another, don’t find their way into a full-length posting on the Genomics Law Report. Last week, thanks to a particularly impressive confluence of client demands, no stories found their way into either full-length postings or Twitter updates. However, after a brief hiatus, the Weekly Twitter Roundup is back. This week we have a plethora of Tweets from @genomicslawyer that highlight developments that caught my eye as I was wading through an RSS backlog of over 3,000 items. Enjoy.

AUS company offers discounted genetic tests if you’ll share the information with your insurers. http://bit.ly/cRmkq3 Impt GINA implications.
Another national biobank in Scandinavia? Norway contemplating commercialization of national biomarker resources: http://bit.ly/cNaDZR (2/18)
Going global, @PathwayGenomics partners with Colombian lab to offer DTC genetic testing: http://bit.ly/cziLCQ? (GenomeWeb, 2/18)
London Sperm Bank brand designed by Silk Pearce http://bit.ly/agYAU6 (HT @MishaAngrist) As donor anonymity declines, will PR fill the void?
Explaining genetics to consumers @PathwayGenomics licenses Harvard-developed content for DTC genetic test reports: http://bit.ly/cnw4WP
Pin the Egg on the Sperm: Couple turns to social media, friends to help defray the cost of IVF/PGD: http://bit.ly/d4hcNB (SFGate, 2/5)
Last tweet re: @CompleteGenomic – it is that kind of number that makes #GET2010 so historic. By 2011, individuals with WGS in the 1,000s
Still catching up, including re: AGBT, but this impresses me: @CompleteGenomic announces 500 genomes in the pipeline: http://bit.ly/abhWNi
Are Sperm Donors Really Anonymous Anymore? http://bit.ly/c9KzOP (Slate, 3/1) The myth of genetic anonymity is increasingly exposed as such.
Eric Lander on the disconnect between science and economics: http://bit.ly/aRG7rU “Health care is ‘rife with market failures’” (WSJ, 2/22)
At AAAS meeting, personal genomic sequencing likened to “publishing a book that cannot be read.” http://bit.ly/91c5Nu (GenomeWeb, 2/23)
Sage Bionetworks to be NCI Center http://bit.ly/dCLKrK (@GenomeWeb_News, 2/23)
FDA’s IVDMIA Guidance Just as ‘Imminent’ today as it was in 2007 http://bit.ly/9ua7Pd (The Sample, 2/25)
Post-DNA Direct acquistion, MedCo plans to move genetic testing from payor-by-payor decision to standard of care http://bit.ly/aMpFfy (2/25)
Your Genome In the Cloud: GenomeQuest Wants to be the Google of DNA Data Searches: http://bit.ly/cLAiC1 (2/25 v @Ryan_McBride)
NHGRI Launches Genomic Education Resource http://bit.ly/aOE9ao (Please bear with me as I move into some news from last week, and before.)
New to Personalized Medicine? MIT’s Technology Review has a great set of introductory articles: http://bit.ly/9Wq4Sb (HT @emilysinger)
Crowdsourcing pharma whistleblowing: http://bit.ly/bxXMAU For those of you with an abundance of free time.
FDA Commish Hamburg: “We have allowed the arm of regulatory science to become weak and underdeveloped” http://bit.ly/9SmpZT Agreed.
If you haven’t heard, @MishaAngrist is now on Twitter. If you aren’t following him, you should. #FollowThursday
RT @markgfh: My latest Science Matters column for Eureka: http://bit.ly/br2l59 On growing demand for embryo screening
After GINA, Where Do Life Insurance Firms Stand on Using Genomic Information for Coverage Decisions? http://bit.ly/dArv8A
Nice profile of Geospiza from @ldtimmerman: whole-genomes, from sequencing to software: http://bit.ly/aza7EC
Catching up on AGBT thanks to MassGenomics (IonTorrent and ipods: http://bit.ly/9CzfWD) and @dgmacarthur http://bit.ly/b2BB2Z
X-Prize Ventures Further Into Biology: New Organs from Stem Cells and New Doctors from Software http://bit.ly/9bPuHl (@crossborderbio)
Struggling to slog through the “trough of disillusionment”? @dgmacarthur on @23andMe and personal genomics http://bit.ly/9JcxWc
Myriad Assures Investors of Strong Patent Position Despite ACLU Anti-Gene Patenting Lawsuit http://bit.ly/a0fQ92
Who drives adoption of EHRs: patients, docs or hospitals? MSFT HealthVault leaning toward hospitals: http://bit.ly/aTijaZ
MSFT Builds Out Health IT Portfolio, Waits (and Waits) for Market to Materialize http://bit.ly/d9hU8m (v @ldtimmerman)
RT @dgmacarthur: Warning from @lindaavey (@23andMe co-founder) of impending NY Times attack piece on personal genomics: http://bit.ly/cdtxMG
I agree with @GeneSherpas: @23andMe and the personal genomics industry as a whole is morphing, not dying.
RT @dgmacarthur: China’s BGI is “on track to surpass the entire sequencing output of the US”: http://bit.ly/a9YrxD /via @d_swan
Shades of 1993: GET Conference to Search for the Killer App in Personal Genetics: http://bit.ly/9NFXhu #GET2010
RT @nanopore: Inside You,150 x more ‘Not You Genes’ than ‘You Genes.’ “Our Other Genome” in Nature http://bit.ly/aDTkCH
RT @dgmacarthur: Genetic genealogist @blaine_5 reviews his Pathway Genomics ancestry results: http://tinyurl.com/yffj7gk
BioReference moving into prenatal genetic testing space, buys regional genetics lab (via The Sample): http://bit.ly/dnmSKr
Francis Collins is on the Diane Rehm show at 11a today to discuss the future of personalized medicine: http://bit.ly/jZer
Redefining privacy in the era of personal genomics http://bit.ly/almOFR Ars Technica on the difficulty of DNA de-identification
From Bench to Market: The Benefits and Limits of Non-Disclosure Agreements: http://bit.ly/bB5o15
RT @humangenomeorg Drinking from the Firehose of Genomic Data: Supercomputing & Genomics http://bit.ly/cDI3a2
The Texas Newborn Blood Spot Saga Continues http://bit.ly/cIpgwJ
A Drug Trial Cycle: Recovery, Relapse, Reinvention (by Amy Harmon, NYT): http://nyti.ms/bqxULA
Genome Boy (aka Misha Angrist) interviewed re: upcoming personal genomics book: http://bit.ly/9UyL4i
Advice for entrepreneurs: Protect yourself with patents and be prepared to fight: http://bit.ly/8ZoCQX